Merck & Co., Inc. 4
4 · Merck & Co., Inc. · Filed Apr 29, 2015
Insider Transaction Report
Form 4
Kuhlik Bruce N
Exec. V.P. and General Counsel
Transactions
- Sale
Common Stock
2015-04-29$59.58/sh−65,306$3,890,886→ 236,391.143 total - Sale
Common Stock
2015-04-29$60.00/sh−91,596$5,495,760→ 144,795.143 total - Exercise/Conversion
Common Stock
2015-04-29$36.56/sh+44,776$1,637,011→ 301,697.143 total - Exercise/Conversion
Stock Option (right to buy)
2015-04-29−112,126→ 56,064 totalExercise: $39.29From: 2013-05-02Exp: 2022-05-01→ Common Stock (112,126 underlying) - Exercise/Conversion
Common Stock
2015-04-29$39.29/sh+112,126$4,405,431→ 256,921.143 total - Exercise/Conversion
Stock Option (right to buy)
2015-04-29−44,776→ 0 totalExercise: $36.56From: 2012-05-04Exp: 2021-05-03→ Common Stock (44,776 underlying)
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.2600 to $59.8500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.8600 to $60.4100, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
- [F3]Holdings include shares acquired in dividend reinvestment transactions.
- [F4]The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015.
- [F5]The option became exercisable in equal installments on 5/4/2012, 5/4/2013 and 5/4/2014.